Investor Presentation

June 2026

ASX:NYR

Authorised by Mr. John Moore, Non-Executive Chair, on behalf of the Board.

Important Notice and Disclaimer

This presentation has been prepared by Nyrada Inc **("NYR"** or **"Company"**). It should not be considered as an offer or invitation to subscribe for, or purchase any securities in NYR, or as an inducement to purchase any securities in NYR. No agreement to subscribe for securities in NYR will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction. In particular, this presentation may not be released to US wire services or distributed in the United States.

This presentation does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or to, or for the account or benefit of, US persons. The Company's CDIs have not been, and will not be, registered under the US Securities Act or the securities laws of any state or other jurisdiction of the United States. The CDIs may not be offered, sold or otherwise transferred in the United States except in a transaction exempt from, or not subject to, the registration requirements of the US Securities Act of 1933 and the applicable securities laws of any state or other jurisdiction in the United States. No person in the United States may, directly or indirectly, participate in the Company's Security Purchase Plan.

It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice, and the Company is not licensed to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place.

Such forward-looking statements do not guarantee of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.

Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making.

Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.

Investment Highlights

Advancing first-in-class TRPC inhibitor with multiple near-term value catalysts

Platform asset with data supporting multiple indications

- Lead asset Xolatryp® targeting TRPC3/6/7 ion channels with broad applicability across cardioprotection, neuroprotection and oncology
- Preclinical efficacy demonstrated in cardiac reperfusion injury, ischemic stroke, traumatic brain injury (TBI) and anti-tumour models
- Multiple development pathways across high unmet need indications supported by a common and novel target

Positive Phase I safety and kinetic data

- Phase I trial successfully completed in 48 healthy volunteers with all doses safe and well-tolerated
- No dose-limiting toxicities or serious adverse events observed
- Linear and predictable pharmacokinetics with rapid therapeutic exposure achieved within 10 minutes
- Supports launch of Phase II trials across multiple indications

Near term Phase IIa safety and efficacy data

- PROTECT-MI Phase IIa trial underway in cardiac reperfusion injury in STEMI patients undergoing PCI
- First clinical site activated and recruitment commenced in May 2026
- 6 sites initially and further sites expected to be activated imminently
- Interim safety data for first 8 patients expected in Q3 CY26

High unmet need opportunity in reperfusion injury with large addressable market

- ~4 million PCI procedures performed globally each year with no approved cardioprotective therapies targeting reperfusion injury[1]
- Reperfusion injury may account for up to ~50% of total heart muscle damage (infarct size) following STEMI heart attack
- Potential to reduce infarct size, prevent arrhythmias, lower risk of heart failure, hospitalisation, and mortality
- US market is an estimated US$3bn opportunity

Strong IP & Uniquely Experienced Team

- Composition of matter patent protection supporting Xolatryp® platform development
- Leadership team with extensive and international experience across translational research and clinical drug development, including at Neuren Pharmaceuticals, and other global clinical programs
- Board with proven track record across biotechnology, pharmaceuticals, commercialisation and capital markets

Multiple near-term catalysts

- Ongoing PROTECT-MI Phase IIa site activation and recruitment updates through CY26
- PROTECT-MI Phase II safety review of first 8 patients expected in Q3 CY26
- PROTECT-MI Phase II topline data anticipated in 2H CY27
- Preclinical cardiomyopathy study expected in Q3 CY26
- Advancement of oncology, ischemic stroke and TBI programs

(1) Complex Percutaneous Coronary Intervention Market Outlook 2025-2034 - https://dataintelo.com/report/complex-percutaneous-coronary-intervention-market-report

About Nyrada

Nyrada is pioneering TRPC-targeted therapies, providing exposure to an emerging and increasingly recognised therapeutic area

- Nyrada Inc (ASX:NYR) is a clinical-stage biotechnology company developing a first-in-class small molecule Transient Receptor Potential Canonical (TRPC) ion channel inhibitor
- Lead drug candidate Xolatryp® targets TRPC3/6/7 channels, a differentiated combination not currently being advanced by other clinical-stage companies
- Most current therapies target downstream consequences of disease, whereas Xolatryp® is designed to address the upstream calcium dysregulation that drives injury
- Validated mechanism, supported by extensive preclinical and Phase I data, creates platform potential across multiple high-value disease areas from a single asset
- Currently targeting applications across indications of high unmet need in cardioprotection, oncology and neuroprotection
- Xolatryp® currently in Phase IIa in cardiac reperfusion injury post ST-elevation myocardial infarction (STEMI)
- Commercially focused business model, experienced leadership team, and board with a demonstrated track-record

Management

Highly experienced and a proven track record of delivering shareholder value

Leadership Team

James Bonnar

Managing Director & CEO

Mr Bonnar is Managing Director and CEO of Nyrada, having joined in February 2018. He is responsible for the overall management and strategic direction of Nyrada.

Mr Bonnar has over 25 years of global experience in the life sciences industry, including preclinical research, operations management, CMC (Chemistry, Manufacturing and Controls), Regulatory Affairs, and QA.

Mr Bonnar was previously at Neuren for 11 years, where he was Director of Clinical Operations and oversaw clinical development for drugs in the areas of traumatic brain injury and neurodevelopmental orders.

At Neuren, Mr Bonnar played a key role in the development of Trofinetide, which became the first FDA-approved treatment for Rett syndrome, sold under the brand name DAYBUE®.

Benny Evison Ph.D

Chief Scientific Officer

Dr Evison has served as Chief Scientific Officer since March 2019 and is responsible for advancing drug development programs from discovery to clinical evaluation.

Dr Evison has over 25 years of experience in drug development across oncology research, DNA repair mechanisms and the progression of novel compounds into human clinical trials.

Prior to joining Nyrada, Dr Evison completed a postdoctoral research fellowship at St Jude Children's Research Hospital in the US.

Alex Suchowerska Ph.D

Director of Clinical Operations and Regulatory Affairs

Dr Suchowerska has served as Director of Clinical Operations and Regulatory Affairs since November 2024 and is responsible for leading clinical operations and oversees the progression of clinical programs.

Prior to her current role, Dr Suchowerska lead the planning and execution of the regulatory package for Xolatryp®.

Dr Suchowerska brings over 10 years experience in preclinical drug development and translational research, with a strong focus on advancing novel therapeutics toward clinical applications.

Jasneet Parmar Ph.D

Director of Research and Development

Dr Parmar has served as Director of Research and Development since December 2024 and is responsible for leading Nyrada's research and development strategy, overseeing the progression of its lead clinical asset, Xolatryp®, from translational research through to clinical development.

Dr Parmar brings over 10 years' experience in ion channel biology and preclinical drug development with deep expertise in TRPC channel biology.

Dr Parmar has played a central role in advancing Nyrada's TRPC inhibitor program from early discovery through preclinical validation and into clinical-stage development.

Dimitri Burshtein

Director of Investor Relations and Corporate Development

Mr Burshtein has served as Director of Investor Relations and Corporate Development since June 2023, leading the Company's investor engagement and corporate development initiatives.

Mr Burshtein brings over 25 years of years of experience across finance, strategy, corporate development, investor relations, and communication.

Prior to joining Nyrada, Mr Burshtein served as Head of Corporate Development and Investor at Spacetalk, Group Executive of Corporate and Strategic Business Development at FEX Global, and General Manager of Corporate Finance and Investor Relations at ASX Ltd.

Board of Directors

Highly experienced and a proven track record of delivering shareholder value

Board Members

John Moore
Non-Executive Chairman

Mr Moore has served as Non-Executive Chairman of Nyrada Inc, since August 2019.

Mr Moore is a seasoned executive with extensive leadership experience across multiple industries across Life Sciences, Medical Equipment and Pharmaceuticals.

Mr Moore currently serves on the boards of two private and three public companies including Director at Cormetech, Inc, and Chair of the Board at Scientific Industries, Inc.

Christopher Cox
Non-Executive Director

Mr Cox has served as a Non-Executive Director of Nyrada Inc, and subsequently the Company since November 2019.

Mr Cox has served as Co-Founder and General Partner of Population Health Partners, L.P. Previously, he served as Partner, Chairman of the Corporate Department, and management committee member at Cadwalader, Wickersham & Taft LLP, and as Executive Vice President and Chief Corporate Development Officer of The Medicines Company.

Marcus Frampton
Non-Executive Director

Mr Frampton has served as a Non-Executive Director of Nyrada Inc, since January 2020.

Mr Frampton currently serves as the Chief Investment Officer of the Alaska Permanent Fund Corporation (APFC), an US$86b sovereign wealth fund.

Dr Rüdiger Weseloh
Non-Executive Director

Dr Weseloh has served as a Non-Executive Director of Nyrada Inc, since June 2019.

Dr Weseloh currently serves as Executive Director of Business Development at EMD Serono, Inc,. a biopharmaceutical division wholly owned by Merck KGaA.

Dr Ian Dixon
Non-Executive Director

Dr Dixon has served as a Non-Executive Director of Nyrada Inc, since 2016

In 2011, Dr Dixon co-founded Cynata Inc, a subsidiary of ASX-listed Cynata Therapeutics Ltd (ASX:CYP). In 2018.

Dr Dixon co-founded Cardio Therapeutics Pty Ltd in 2014 which was acquired by Nyrada Inc, in 2019.

James Bonnar
Managing Director & CEO

Refer to Management slide

Xolatryp®

Nyrada's lead candidate Xolatryp® is a novel gatekeeper of calcium influx with wide applicability

Overview

- Xolatryp® is a third generation TRPC3/6/7 channel inhibitor
- Highly differentiated, proven target with well understood mechanism-of-action
- TRPC ion channels act as an upstream control point for pathological Ca^{2+} influx, offering broad therapeutic potential relative to downstream pathway targets
- In normal state, TRPC maintains physiological ion channel equilibrium in brain, heart, kidney, lung and immune systems



Cardioprotection

TRPC3 TRPC6 TRPC7

- ↓ Cell death (preserve function)
- ↓ Oxidative stress
- ↓ Arrhythmia
- ↓ Fibrosis & Cardiovascular scarring
- ↑ Cardiac remodelling

Neuroprotection

TRPC3 TRPC6 TRPC7

- ↓ Cell death (preserve function)
- ↓ Inflammation (impaired regulation)
- ↓ Swelling
- ↓ Immune response

Oncology

TRPC3 TRPC6 TRPC7

- ↓ Cell proliferation & migration (metastatic spread)
- ↓ Drug resistance
- ↓ Cell invasion
- ↓ Tumour progression

Xolatryp®

Highly focused multi-indication platform addressing high unmet need in well-defined markets

1
Candidate

3
Current Applications

4
Current Target Markets

Xolatryp®

Cardioprotection

Cardiac Reperfusion Injury

- **Phase IIa recruiting**
- **Up to 50% of heart injury** may be caused by reperfusion
- **No approved pharmacological therapies** to treat reperfusion injury
- ~4m PCI procedures performed globally and ~900k p.a. in the US[1]
- **Well characterised market** – acute setting, clinician-dosed, no compliance risk

Oncology

Adjunct in Anthracycline-treated Cancers

- Demonstrated additive effect in tumour volume reduction in preclinical model with 1st line chemotherapy
- **41% reduction in tumour volume** (Xolatryp® + Doxorubicin) vs Doxorubicin alone in a liver cancer CDX animal model
- Parallel assessment ongoing in anthracycline-induced cardiac damage animal model with the potential for dual therapeutic action in anthracycline-treated patients
- Potential for Phase Ib/II in patients receiving doxorubicin-based therapy

Neuroprotection

(secondary brain injury)

Traumatic Brain Injury (TBI)

- **Phase II ready** in the prevention of secondary brain injury following primary TBI
- Statistically significant preclinical neuroprotection confirmed
- **No approved pharmacological therapies** to treat TBI
- ~220,000 TBI-related ED visits p.a. (US) - per CDC[2]
- ~70,000 TBI-related deaths (US) - per CDC[2]

Ischemic Stroke

- **Phase II eligible** following single additional preclinical model
- Statistically significant preclinical neuroprotection confirmed
- ~700,000 Ischemic strokes in US p.a. - per CDC[3]
- **Existing treatment (tPA's) suitable for <15% of cases**

Note: Landscape includes publicly disclosed programs. Other early-stage programs also exist.
(1) Percutaneous Coronary Intervention (PCI) - https://www.yalemedicine.org/conditions/percutaneous-coronary-intervention-pci?utm
(2) TBI Data - https://www.cdc.gov/traumatic-brain-injury/data-research/index.html
(3) Stroke Facts - https://www.cdc.gov/stroke/data-research/facts-stats/index.html

Xolatryp® Phase I Clinical Trial

Primary endpoint met with all doses safe and well-tolerated, with no dose-limiting, or dose-related safety issues

Trial Overview

- Phase I, randomised, double-blind, placebo-controlled study in 48 healthy volunteers
- 36 received Xolatryp®, 12 received placebo across 6 ascending dose cohorts
- Positive final review received in August 2025

Safety Outcome

- No dose-limiting toxicities, no safety signals, no serious adverse events (SAEs)
- All reported adverse events were mild or moderate

Pharmacokinetics

- Linear, predictable PK with consistent clearance and stable volume of distribution
- Therapeutic levels within 10 min; maintained well above IC_{90} for longer than 6 hours

Supports launch of Phase II trials across multiple indications



<10 min
to reach therapeutic levels

>6 hours
well above IC_{90}

Diversified Pipeline

Multiple compelling TRPC opportunities in indications of high unmet need

Applications	Target Indication	Pre-clinical	Phase I	Phase II	Phase III
Cardioprotection	Cardiac Reperfusion Injury Post STEMI			*Phase IIa Recruiting*	
Oncology	Chemotherapy Induced Cardiomyopathy		*Proof of concept demonstrated*		
	Adjunct Anthracycline Anti-tumour Treatment			*Phase Ib ready*	
Neuroprotection	Ischemic Stroke		*Preclinical efficacy demonstrated*	*Phase II ready subject to 2nd preclinical study*	
	Traumatic Brain Injury (TBI)			*Phase II ready*	

TRPC Channels: Clinical Landscape & Validation

Growing Clinical Interest in TRPC modulation across major disease areas

- Genetic validation and strong preclinical data have led to advancing clinical programs across cardiovascular, kidney, neurological and fibrotic diseases
- Both large pharma and biotech are now advancing TRPC-targeted therapies into Phase II/III trials, confirming clinical actionability

Clinical Landscape for TRPC Targeted Therapies

Company	Program/ Target	Indication	Phase	Status/Milestones
Boehringer Ingelheim	Apecotrep (BI 764198) TRPC6 inhibitor	Primary FSGS (kidney disease)	Phase III	• Phase III results published in The Lancet (Jan 2026). • 40% proteinuria reduction vs. placebo. Phase III. • (NCT07220083) now recruiting. • Phase II expansion to other proteinuric diseases underway.
Boehringer Ingelheim	BI 1358894 TRPC4/5 inhibitor	Major Depressive Disorder (MDD)	Phase II Completed	• Phase II dose-ranging trial completed (J Clin Psychiatry, Sept 2025). • Efficacy not demonstrated; drug well-tolerated. • Further development path under evaluation.
Bristol Myers Squibb	TRPC4/5 inhibitor program	Mood and anxiety disorder	Phase I	• Phase I SAD/MAD completed (2023). No publicly disclosed Phase II advancement to date.
Nyrada inc	Xolatryp® TRPC3/6/7 inhibitor	Cardioprotection, Neuroprotection, Oncology	Phase II Recruiting	• PROTECT-MI Phase IIa trial recruiting STEMI patients. Interim safety review for first 8 patients expected Q3 CY26.

First TRPC Program to Reach Phase III

- Boehringer Ingelheim's Apecotrep is a first-in-class, oral, selective TRPC6 inhibitor in primary FSGS - a rare, progressive kidney disease with no approved targeted therapies. The Phase II trial (NCT05213624) enrolled 67 patients across 31 centres in 10 countries.
- **Study:** Phase II randomised, double-blind, placebo-controlled (NCT05213624)
- **Population:** Adults with primary FSGS or genetic TRPC6-mutation FSGS
- **Primary Endpoint**: ≥25% reduction in urine protein: creatinine ratio (UPCR)
- **Key Result:** 40% reduction in proteinuria (20mg dose) vs. placebo (p=0.002); published in The Lancet, January 2026
- **Next Step:** Phase III trial (NCT07220083) now recruiting (286 patients, 104-week study). Phase II expansion to other proteinuric kidney diseases also initiated.

This represents the most advanced clinical program targeting a TRPC channel and is a major near-term catalyst validating the class

Broad Therapeutic Potential Across TRPC Subtypes

Cardiovascular	Renal	Neurological / CNS	Oncology
Ischemia-reperfusion injury, heart failure, arrhythmias (TRPC3/6/7)	FSGS, diabetic kidney disease, proteinuric glomerular diseases (TRPC6)	MDD, anxiety, stroke, TBI, neurodegeneration (TRPC3/4/5/6/7)	Cardioprotection and antiproliferative cancer treatment (TRPC3,6,7)

Strong clinical validation: Boehringer Ingelheim's Apecotrep has become the first TRPC inhibitor to reach Phase III (FSGS, Jan 2026), validating TRPC6 as a disease target. Blue-chip pharma investment across multiple TRPC subtypes confirms the class as clinically actionable. Nyrada's Xolatryp® is the only programme targeting TRPC3/6/7 in cardioprotection, oncology and neuroprotection.

Xolatryp® in Cardiac Reperfusion Injury

Well defined & uncontested $US3bn market opportunity

Heart Attack (STEMI)

STEMI results in a hyper-activation of TRPC channels

Overview

- Atherosclerotic plaque restricts blood flow to a region of the heart muscle resulting in Myocardial Infarction (MI) “Heart attack”
- Myocardium oxygen demand exceeds supply
  - **Within seconds**: Cells Shift towards emergency source of energy (anaerobic glycolysis)
  - **Within minutes**: Ion pumps fail, Ca^{2+} floods cardiac tissue → contractile dysfunction begins
  - **Within 20-40 minutes**: Irreversible cardiac cell tissue necrosis begins in the most oxygen deprived zones
- Release of cardiac biomarkers into the bloodstream (troponin I/T, CK-MB)
- Inflammatory response drives activation of fibroblast-drive scar tissue
- Compensatory hypertrophy of surviving tissue → driver of heart failure



Fatty cholesterol plaque builds up inside a coronary artery (the vessels supplying the heart with blood), forming a clot that completely blocks flow - starving heart muscle of oxygen.

STEMI

- STEMI (ST-elevation myocardial infarction) is a blockage
- Elevated ST segment on ECG
- Urgent reperfusion via Percutaneous Coronary Intervention (PCI) **ideally within ~90 minutes**
- ~30% of all MI cases; carry higher acute mortality
- ~7 million acute coronary syndrome (ACS) cases p.a. globally
- Compensatory hypertrophy of surviving tissue → driver of heart failure



An ECG (electrocardiogram) records the heart's electrical activity. In a normal heartbeat the ST segment is flat. In STEMI, the ST segment is elevated - signalling a complete blockage requiring immediate treatment.

Acute ST-Segment Elevation Myocardial Infarction (STEMI) - https://www.ncbi.nlm.nih.gov/books/NBK532281

Current Standard Treatment for STEMI Heart Attack

Up to ~50% of heart injury may be caused by reperfusion

Current Standard of Care for STEMI patients

- Percutaneous Coronary Intervention (PCI) is the standard of care for STEMI patients by early 2000s
- ~4 million PCI procedures p.a. globally[1]



The Clinical Paradox from PCI

- Although timely PCI restores coronary blood flow and limits ischemic injury, reperfusion itself can trigger additional myocardial damage
- The abrupt restoration of blood flow drives rapid Ca^{2+} overload, oxidative stress, mitochondrial dysfunction and inflammatory signalling
- **Reperfusion injury may account for up to ~50% of final infarct size** in STEMI patients following PCI[2]
- Despite strong mechanistic rationale, no approved pharmacological therapy currently exists to directly reduce reperfusion injury



Infarct size as a driver of heart failure risk and mortality

Review of multiple clinical studies show that reducing heart muscle damage lowers risk of heart failure hospitalisation[3]

- 5% reduction in infarct size → ~17% lower risk of heart failure hospitalisation
- 10% reduction in infarct size → ~31% lower risk of heart failure hospitalisation
- Patients with the largest infarcts have >7× higher risk of death or hospitalisation

Potential for Xolatryp® to reduce infarct size → clinically significant reduction in adverse cardiac events and improved quality of life

(1) Analyst Q&A: Coronary Balloon Catheters and the Global Market - https://idataresearch.com/analyst-qa-coronary-balloon-catheters-and-the-global-market
(2) Reducing myocardial infarct size: challenges and future opportunities - https://heart.bmj.com/content/102/5/341
(3) Relationship Between Infarct Size and Outcomes at 12 Months Following Primary PCI: Patient-Level Analysis From 10 Randomized Trials www.pubmed.ncbi.nlm.nih.gov/27056772/

Large, Uncontested Market Opportunity

A large, uncontested US$3bn US opportunity

US Market Opportunity

~750K
STEMI[1]
Annual STEMI incidence in the US

>80% ×

~600K
STEMI related PCI[1]
Estimated PCI procedures related to STEMI

×

US$5,000
Illustrative price[2]
Illustrative price per procedure

=

US$3bn
Total addressable market in the US

Potential future expansion into broader 4m global PCI procedure market
(~900k PCI's in the US alone)[3]

(1) Continuous quality improvement for prehospital STEMI improved triage rates and achievement of gold standard <90-min EMS-to-balloon time - https://pmc.ncbi.nlm.nih.gov/articles/PMC11905686/
(2) Based on TNKase (Tenecteplase) cost of ~US$5-10k
(3) Percutaneous Coronary Intervention (PCI) - https://www.yalemedicine.org/conditions/percutaneous-coronary-intervention-pci?utm

Xolatryp® Cardioprotective Function

Strong, consistent cardioprotection across models of myocardial infarction

Two preclinical studies evaluated Xolatryp® in myocardial ischemia-reperfusion (I/R) injury models. One assessed early arrhythmia events and biomarkers over **3 hours**, the other assessed infarct size and heart function over **24 hours**.

24-hour Infarct size study

Assessed after 24 hours

Cardioprotection following Ischemia-Reperfusion (I/R) Injury

Xolatryp® showed strong efficacy limiting cardiovascular damage resulting from cardiac reperfusion injury

- **86%** Cardioprotection (Infarct volume)
- **43%** Increase in left ventricular ejection fraction
- **50%** Increase in fractional shortening

Key blood biomarker markers assessed

- **42%** Decrease in AST levels
- **45%** Decrease in LDH levels
- **32%** Decrease in Cardiac Troponin I

Superior efficacy compared to FDA-approved, Captopril

24-hour study measured infarct size and heart function after ischemia-reperfusion injury. Results show reduced heart muscle damage and improved cardiac performance.



3-hour Arrythmia & Biomarker Study

Assessed over 3 hours

Myocardial Infarction

Xolatryp® showed strong efficacy limiting cardiovascular damage resulting from cardiac reperfusion injury when administered as a short-duration intravenous infusion.

- **42%** Cardioprotection (indicated by infarct volume)
- **88%** Decrease in arrhythmias at 1 hour
- **90%** Decrease in arrhythmias at 3 hours

Key blood biomarker markers assessed

- **32%** decrease in Cardiac Troponin I
- **21%** decrease in ALT levels

3-hour study focused on early arrhythmias and biomarker response. Results show rapid protection alongside reduced heart muscle damage and improved cardiac function



Together, these studies demonstrate that Xolatryp® provides both early and sustained cardioprotection in preclinical models.

PROTECT-MI: Phase IIa Trial Design

Phase IIa cardiac reperfusion Injury clinical trial currently recruiting

PROTECT-MI is a Phase IIa randomised, double-blind, placebo-controlled study evaluating Xolatryp® in STEMI patients undergoing PCI

- The trial is designed to assess safety, tolerability and preliminary efficacy in reducing cardiac reperfusion injury, with topline data expected in 2H CY27.
- Phase IIa study targeting a significant unmet need in STEMI reperfusion injury
- Designed to generate early efficacy and safety data to support future pivotal development
- Australian multicentre rollout underway with recruitment initiated
- Key catalysts:
  - Site activation updates
  - Recruitment progress
  - Interim safety review
  - Topline data in Q3 CY27 Potential validation of Xolatryp® across broader cardiovascular indications

Size	100 evaluable patients (placebo and drug randomisation – 1:1)
Timeline	~9 to 18 months following first site activation (indicative)
Sites	6 sites initially (Australia)
First patient screened	May 2026
Top-line data timing	2H CY27
Primary endpoint	Safety and tolerability
Efficacy endpoints	• Cardiac MRI infarct sizing • Biomarkers, including Troponin I levels • Cardiac function • Incidence of arrhythmias of interest

Other Indications across Oncology & Neuroprotection

Oncology

Xolatryp® enhances anthracycline anti-tumour efficacy

Xolatryp® Enhances Standard Chemotherapy Efficacy

- Novel TRPC3/6/7 inhibitor targeting calcium-dependent tumour growth pathways
- Anthracyclines remain a cornerstone of cancer treatment, but use is limited by dose-dependent toxicity
- No approved adjunct therapies are specifically designed to enhance anthracycline anti-tumour activity
- Demonstrated additive anti-tumour activity in combination with doxorubicin in a preclinical liver cancer model
- 57% reduction in tumour volume when combined with doxorubicin vs vehicle control
- ~39% improvement in anti-tumour efficacy compared with doxorubicin alone
- Combination treatment showed earlier tumour suppression
- Existing Phase I human safety data supports clinical translation

Key Takeaway

- Xolatryp® enhanced the efficacy of standard-of-care chemotherapy, delivering greater tumour growth inhibition than chemotherapy alone in a preclinical liver cancer model
- Potential to improve anthracycline therapeutic response without increasing chemotherapy dose intensity
- Clear pathway to rapid clinical validation in Phase Ib combination study
- Preclinical animal study underway to explore cardioprotection in doxorubicin-induced cardiomyopathy – pilot study completed June CY26



Neuroprotection

Xolatryp® targets secondary injury following ischemic stroke and traumatic brain injury

Overview

- Ischemic stroke and traumatic brain injury (TBI) trigger secondary injury pathways that drive ongoing neuronal damage
- Excess intracellular Ca^{2+} is a key mediator of excitotoxicity, mitochondrial dysfunction and neuronal cell death
- TRPC3/6/7 channels contribute to pathological calcium influx following acute brain injury
- No approved therapies directly target calcium-driven secondary injury mechanisms
- Xolatryp® is designed to inhibit TRPC3/6/7-mediated Ca^{2+} overload and interrupt the secondary injury cascade
- Demonstrated statistically significant neuroprotection in both ischemic stroke and severe TBI preclinical models
- 42% neuroprotection observed in the stroke penumbra with a 41% reduction in NfL levels
- Significant neuroprotection confirmed in a severe TBI model conducted with the Walter Reed Army Institute of Research (WRAIR) and UNSW Sydney

Key Takeaways

- Xolatryp® targets a common upstream driver of neuronal injury across both stroke and TBI
- Preclinical studies demonstrate significant neuroprotection across multiple brain injury models
- Existing human Phase I safety data provides a foundation for future clinical development in acute neuroprotection



Catalysts

Upcoming milestones over the next 18 months

2H CY26

- PROTECT-MI Phase IIa execution: ongoing patient recruitment and site activations across Australian PCI-capable hospitals
- PROTECT-MI Phase IIa interim safety data for first 8 patients
- Potential expansion of PROTECT-MI Phase IIa trial site network, with flexibility to add hospitals in Australia or internationally
- PROTECT-MI Phase IIa FDA IND preparation and submission pathway
- Ongoing updates from preclinical oncology and cardioprotection studies
- Completion of preclinical cardiomyopathy study
- Evaluation of other oncology drug classes in combination with Xolatryp®

1H CY27

- PROTECT-MI Phase IIa execution: ongoing patient recruitment and site activations
- Continued build-out of Xolatryp® beyond heart attack: oncology, stroke/TBI and other ischemia-reperfusion applications

2H CY27

- Phase IIa PROTECT-MI completion and topline data
- Safety, biomarker, arrhythmia, cardiac MRI/infarct-size and cardiac-function data with potential first patient efficacy signals
- Positive data from Phase IIa PROTECT-MI would support partnering, larger Phase IIb/III planning, and broader platform validation for TRPC inhibition

Appendix

Corporate Overview & Financial Snapshot

Key Details

Stock Code	ASX:NYR
Share Price (1 June 2026)	A$0.48
Number of CDIs on Issue	245m
Market Capitalisation (1 June 2026)	A$119.0m
Pro forma Cash Balance (31 March 2026)[1]	A$9.19m
Numbers of Shareholders	2,448
Board & Management Ownership	11.7%

Modest Overheads – majority of capital deployed towards R&D

Item	FY25 (A$ million)	FY24 (A$ million)
R&D Costs	*4.4*	*2.0*
Corporate and admin expenses	*1.1*	*0.6*
Professional services expense	*0.4*	*0.5*
Employment benefits expense	*1.2*	*1.1*

Share Price Chart – Last 24 months



S&P Capital IQ as of 02 June 2026
[1]Includes A$2.45 million R&D tax rebate received May 2026

Program Links

- PROTECT-MI website - https://www.protect-mi.com
- Corporate presentation/about MI - https://bit.ly/4dDWNCz
- Phase IIa factsheet - https://bit.ly/4bcDlKj
- Phase I results - https://bit.ly/3Nt0GzH
- GLP study results - https://bit.ly/4d8VYkX
- Preclinical anti-tumour study - https://bit.ly/49rWOa0
- Preclinical cardioprotection study 1a - https://bit.ly/4sigwMZ
- Preclinical cardioprotection study 1b - https://bit.ly/4rmOsXn
- Preclinical cardioprotection study 2 - https://bit.ly/40jHpUg
- Preclinical traumatic brain injury study - https://bit.ly/40fhrRT
- Preclinical stroke study - https://bit.ly/4sygHmH